ArticleCancer pathogenesis and therapy2025
Economic burden and health-related quality of life in Chinese patients with mycosis fungoides and Sézary syndrome.
Article in Cancer pathogenesis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Sleep Disorders and Quality of Life in Patients With Mycosis Fungoides.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The health-related quality of life (HRQoL), economic burden, and diagnostic and treatment status of Chinese patients with mycosis fungoides (MF) and Sézary syndrome (SS) remain largely unknown. This study assessed patient characteristics, HRQoL, and economic burden among Chinese patients with MF and SS through a cross-sectional survey. Methods: Eligible patients were aged ≥18 years with a pathologically confirmed diagnosis of MF or SS and were either currently receiving or had received disease-specific treatment within the past year. Patients completed a paper-based quantitative survey covering four components: patient demographics, diagnosis and treatment journey, economic burden, and HRQoL instrument. Results: Between July 21, 2022, and October 24, 2022, 61 eligible patients participated in this study, of whom 91.8% (56/61) had MF and 8.2% (5/61) had SS. The total cost for patients with MF and SS was Chinese Yuan (CNY) 86,729 (US Dollar [USD] 12,425). The total cost for patients with early-stage disease was significantly lower than that for patients with advanced-stage disease (CNY 43,379 Conclusions: Chinese patients with MF or SS, especially advanced-stage patients, experience high economic burden and compromised HRQoL, which underscore the need for improved access to affordable treatments and supportive care measures to reduce the financial burden and enhance the well-being of these patients. Healthcare policies and interventions should prioritize early diagnosis and effective management to improve the treatment outcome and reduce its associated costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.